{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:27:27Z","timestamp":1787218047412,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jpba.2016.09.047","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T20:16:27Z","timestamp":1475784987000},"page":"184-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Development and characterization of the voriconazole loaded lipid-based nanoparticles"],"prefix":"10.1016","volume":"132","author":[{"given":"Petra","family":"F\u00fcredi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia Edit","family":"P\u00e1pay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00f3f","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5774-7880","authenticated-orcid":false,"given":"Borb\u00e1la Dalmadi","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Lud\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Antal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Klebovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.09.047_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mimet.2016.02.005","article-title":"Searching new antifungals: the use of in vitro and in vivo methods for evaluation of natural compounds","volume":"123","author":"Scorzoni","year":"2016","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.jpba.2016.09.047_bib0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1517\/13543776.2016.1146693","article-title":"Antifungal drugs combinations: a patent review 2000\u20132015","volume":"26","author":"Svetaz","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jpba.2016.09.047_bib0015","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","article-title":"A new triazole voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei","volume":"41","author":"Sanati","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2016.09.047_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jpba.2016.09.047_bib0025","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1128\/AAC.05841-11","article-title":"Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia","volume":"56","author":"Oude Lashof","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2016.09.047_bib0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1078155210396576","article-title":"The effect of enteral nutrition supplements on serum voriconazole levels","volume":"18","author":"Williams","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jpba.2016.09.047_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2016.09.047_bib0040","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1128\/AAC.01126-08","article-title":"Preparation and stability of voriconazole eye drop solution","volume":"53","author":"Dupuis","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2016.09.047_bib0045","first-page":"9","article-title":"Design and evaluation of voriconazole eye drops for the treatment of fungal keratitis","volume":"2014","author":"Malhotra","year":"2014","journal-title":"J. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2334-13-14","article-title":"Evaluation of intravenous voriconazole in patients with compromised renal function","volume":"13","author":"Lilly","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jpba.2016.09.047_bib0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000371712","article-title":"Cytotoxic effect of voriconazole on human corneal epithelial cells","volume":"54","author":"Sobolewska","year":"2015","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jpba.2016.09.047_bib0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejps.2014.07.013","article-title":"Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis","volume":"63","author":"Ustundag-Okur","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2016.09.047_bib0065","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3109\/03639045.2013.795582","article-title":"Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies","volume":"40","author":"Li","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0070","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3109\/02713680903261405","article-title":"Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes","volume":"34","author":"Gokce","year":"2009","journal-title":"Cur. Eye Res."},{"key":"10.1016\/j.jpba.2016.09.047_bib0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/10611860903338462","article-title":"Preparation characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system","volume":"18","author":"Kalam","year":"2010","journal-title":"J. Drug Targ."},{"key":"10.1016\/j.jpba.2016.09.047_bib0080","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/03639045.2010.522193","article-title":"Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo","volume":"37","author":"Liu","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1517\/17425247.2010.525230","article-title":"Topical delivery of antifungal agents","volume":"7","author":"Kaur","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jpba.2016.09.047_bib0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-5173(02)00080-7","article-title":"Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin","volume":"238","author":"Cavalli","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(99)00417-2","article-title":"Influence of high pressure homogenisation equipment on nanodispersions characteristics","volume":"196","author":"Liedtke","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1248\/cpb.c14-00202","article-title":"Improved skin delivery of voriconazole with a nanostructured lipid carrier-based hydrogel formulation","volume":"62","author":"Song","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jpba.2016.09.047_bib0105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/ICO.0000000000000825","article-title":"Voriconazole-loaded nanostructured lipid carriers for ocular drug delivery","volume":"35","author":"Andrade","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.jpba.2016.09.047_bib0110","doi-asserted-by":"crossref","first-page":"6590361","DOI":"10.1155\/2016\/6590361","article-title":"Design and evaluation of voriconazole loaded solid lipid nanoparticles for ophthalmic application","volume":"2016","author":"Khare","year":"2016","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jpba.2016.09.047_bib0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2016.06.027","article-title":"Development and characterization of voriconazole loaded nanoparticles for parenteral delivery","volume":"510","author":"F\u00fcredi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0120","first-page":"122","article-title":"Demystifying dumulcents","volume":"13","author":"Abelson","year":"2006","journal-title":"Rev. Ophthalm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/019262339802600205","article-title":"Ocular irritation: microscopic changes occurring over time in the rat with surfactants of known irritancy","volume":"26","author":"Maurer","year":"1998","journal-title":"Tox. Pathol."},{"key":"10.1016\/j.jpba.2016.09.047_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2016.09.047_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2013 a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0140","first-page":"8","article-title":"Solid lipid nanoparticles- a review","volume":"5","author":"Yadav","year":"2013","journal-title":"Int. J. Appl. Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0145","first-page":"392","article-title":"Study of solid lipid nanoparticles with respect to particle size distribution and drug loading","volume":"58","author":"Patravale","year":"2003","journal-title":"Die Pharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/jop.2012.0069","article-title":"Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation","volume":"29","author":"Hippalgaonkar","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2016.09.047_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","article-title":"Nanoparticles for drug delivery: the need for precision in reporting particle size parameters","volume":"69","author":"Gaumet","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2016.09.047_bib0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/10837459809009857","article-title":"Production of microparticles by high-pressure homogenization","volume":"3","author":"Calvor","year":"1998","journal-title":"Pharm. Dev. Technol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516307610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516307610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:53:39Z","timestamp":1760000019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516307610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":32,"alternative-id":["S0731708516307610"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.09.047","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of the voriconazole loaded lipid-based nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.09.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}